Clinical trial / 2011
Adding extended-release niacin to statin therapy did not reduce cardiovascular events despite improving HDL cholesterol and triglyceride levels.
Researchers randomized 3,414 patients with cardiovascular disease to receive extended-release niacin (1500 to 2000 mg/day) or placebo alongside simvastatin (plus ezetimibe as needed). The trial was stopped after a mean follow-up of 3 years due to lack of efficacy. At 2 years, niacin significantly increased median HDL cholesterol (from 35 to 42 mg/dL) and lowered triglycerides (164 to 122 mg/dL) and LDL cholesterol (74 to 62 mg/dL). However, the primary composite end point occurred in 16.4% of the niacin group and 16.2% of the placebo group (hazard ratio, 1.02; 95% CI, 0.87 to 1.21; P=0.79).
- Study type
- Randomized controlled trial
- Who was studied
- 3,414 patients with established cardiovascular disease and low HDL cholesterol receiving simvastatin therapy
- What was measured
- Composite of death from coronary heart disease, nonfatal MI, ischemic stroke, acute coronary syndrome hospitalization, or revascularization
THE PAPER
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. N Engl J Med, 2011.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.